Metabolic syndrome (MetS) is classically defined as a clustering of central adiposity, atherogenic dyslipidemia characterized by elevated triglycerides and low high-density lipoprotein cholesterol, elevated blood pressure, and hyperglycemia that co-occur more often than expected by chance and substantially elevate cardiometabolic risk [1]. MetS operational definitions from major societies—including the updated Adult Treatment Panel III criteria and the 2009 joint interim statement—established harmonized cut points for each component and catalyzed widespread clinical and epidemiologic adoption [1, 2]. In U.S. adults, MetS is common and has increased over recent decades, with nationally representative analyses indicating that roughly one-third to more than two-fifths of adults meet criteria depending on the cycle and definition used [3, 4]. The public health burden of MetS is substantial because the syndrome confers approximately a twofold higher risk of cardiovascular events and materially greater all-cause mortality independent of traditional risk factors [5]. MetS also identifies individuals at heightened risk for incident type 2 diabetes mellitus and accelerated atherosclerosis, reflecting interlocking pathophysiology that spans insulin resistance, adipose dysfunction, endothelial stress, and chronic low-grade inflammation [6].

Despite the prevalence and prognostic import of MetS, clinical detection often occurs late in the trajectory of cardiometabolic deterioration, leaving a preclinical window in which low-cost screening could refine risk stratification and enable targeted prevention [3]. Contemporary diagnostic and risk tools emphasize anthropometry, blood pressure, fasting glucose, and standard lipid chemistries, whereas simple hematologic indices available from the routine complete blood count (CBC) are absent from diagnostic criteria and are rarely leveraged for MetS screening in practice [1]. The absence of CBC-derived markers in prevailing MetS frameworks reflects historical emphasis on metabolic parameters, yet the hematopoietic system is tightly coupled to immunometabolic signaling and may capture early inflammatory and thrombo-inflammatory shifts relevant to cardiometabolic risk [6].

There is compelling biologic rationale to consider platelets—both their circulating counts and activation state—at the intersection of metabolism and inflammation [7]. Thrombopoiesis is regulated by hepatic production of thrombopoietin (TPO), which is modulated by inflammatory cytokines such as interleukin-6 (IL-6) and by platelet mass–dependent clearance pathways, creating a dynamic feedback loop linking innate immune signaling to platelet biogenesis [8]. Experimental and translational studies demonstrate that IL-6 can drive reactive thrombocytosis via induction of hepatic TPO transcription and secretion, and neutralization of TPO abrogates IL-6–induced platelet expansion, underscoring a mechanistic axis from cytokine tone to megakaryopoiesis [9]. Obesity and adipose tissue inflammation further perturb bone-marrow niches and megakaryocyte biology, with reviews and preclinical models documenting inflammatory reprogramming of megakaryocytes and altered platelet outputs in pro-inflammatory metabolic states [10]. Observational human data also shows that higher adiposity is associated with higher platelet counts and heightened prothrombotic tendency, suggesting a hematologic signature of metabolic stress [11].

Beyond biogenesis, platelets act as effector cells in vascular beds, amplifying endothelial dysfunction and participating in insulin resistance through paracrine mediators and cell–cell crosstalk [12]. Mechanistic and clinical reviews in diabetes and metabolic syndrome describe a milieu of platelet hyperreactivity and endothelial impairment, with hyperglycemia, dyslipidemia, and oxidative stress converging to potentiate platelet activation and impair nitric oxide bioavailability [12]. Insulin normally exerts antithrombotic effects on platelets; however, insulin resistance diminishes these effects, promoting a proaggregatory phenotype that can, in turn, exacerbate vascular inflammation and metabolic dysregulation [13]. Human experimental work indicates that intact insulin action dampens platelet–collagen interactions in vivo, whereas insulin-resistant states abrogate this protective modulation, further linking platelet biology to metabolic homeostasis [14]. These reciprocal relationships support the plausibility that even “high-normal” platelet counts could encode early risk information related to metabolic dysfunction and low-grade inflammation before overt clinical events [15].

Epidemiologic signals connecting platelet indices to cardiometabolic traits are emerging but inconsistent [15]. Several cross-sectional and cohort studies report that higher platelet count and derived inflammatory ratios such as the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) associate with adverse metabolic phenotypes and MetS presence or severity, implying that hematologic indices might reflect systemic inflammatory tone relevant to cardiometabolic risk [16]. Conversely, other population studies—across diverse settings—find null or attenuated associations after adjustment for confounders, highlighting potential issues of reverse causation, residual confounding, measurement heterogeneity, and limited power [17]. Mean platelet volume (MPV), a surrogate of platelet activation, has also been linked to obesity and cardiometabolic risk in meta-analyses and large cohorts, yet reproducibility across metabolic endpoints remains heterogeneous [18]. Within this broader literature, there is a notable paucity of large, nationally representative analyses that evaluate whether platelet count within the reference range carries independent information for MetS beyond adiposity, lifestyle, sociodemographic factors, and systemic inflammatory burden [3].

High-sensitivity C-reactive protein (hs-CRP) is a robust biomarker of low-grade systemic inflammation and a validated predictor of cardiometabolic events, with consensus thresholds of < 1, 1–3, and > 3 mg/L used to denote low, intermediate, and high inflammatory risk categories, respectively [19]. These thresholds have been widely adopted in cardiovascular risk assessment and capture residual inflammatory risk not explained by standard risk factors, rendering hs-CRP an attractive candidate to modify or mediate potential platelet–MetS relationships [20]. Stratification by hs-CRP may be particularly informative because IL-6–TPO–megakaryocyte signaling increases platelet output during inflammatory activation, potentially obscuring or exaggerating any independent association between platelet count and metabolic risk if inflammation is not explicitly modeled [21]. Despite this biologic rationale, few population-based studies have interrogated effect modification by hs-CRP on platelet–MetS associations with adequate control for confounding and complex survey design, leaving a critical evidence gap on whether platelet counts add clinically useful information for MetS screening [5].

National Health and Nutrition Examination Survey (NHANES) data offer a unique opportunity to address this gap because the program collects standardized physical measurements, laboratory assessments—including CBC and hs-CRP—in mobile examination centers using a complex, multistage probability design that yields estimates representative of the noninstitutionalized U.S. population [22]. The survey’s publicly available documentation, sample design reports, and analytic guidelines enable appropriate variance estimation, weighting, and cycle pooling for cardiometabolic research questions that require careful attention to fasting subsamples and laboratory subsampling [23]. Prior NHANES analyses have characterized contemporary prevalence trends of MetS, but few have leveraged the CBC to explore whether platelet indices contribute incremental risk stratification for MetS across inflammatory strata [3].

The present study therefore investigates whether platelet count—treated both as a categorical exposure across clinically interpretable bands and as a continuous exposure with flexible, restricted cubic splines—associates with prevalent MetS among U.S. adults after multivariable adjustment for demographics, adiposity, socioeconomic status, and lifestyle factors using nationally representative NHANES cycles [22]. Because systemic inflammation may confound, mediate, or modify a platelet–MetS relationship, we prespecified analyses stratified by hs-CRP ≤ 3 versus > 3 mg/L, a cut point aligned with consensus cardiovascular inflammatory risk categories, to evaluate heterogeneity of association across inflammatory states [19]. Collectively, these aims test the hypothesis that high-normal platelet counts provide independent early risk information for MetS, particularly among individuals with elevated hs-CRP, and assess whether dose–response relationships are linear or exhibit threshold effects within the reference range.

The primary objective is to test whether higher platelet count—operationalized as both categorical and continuous exposures—is independently associated with prevalent MetS in a nationally representative sample of U.S. adults after adjustment for age, sex, race/ethnicity, socioeconomic status, adiposity, smoking, physical activity, and hs-CRP. Secondary objectives are to characterize the dose–response and potential nonlinearity of the platelet–MetS relationship using restricted cubic splines and to evaluate effect modification by systemic inflammation via stratified analyses at hs-CRP ≤ 3 versus > 3 mg/L. We hypothesize that individuals with high-normal platelet counts will have higher adjusted odds of MetS compared with those in the mid-normal range and that this association will be stronger among participants with hs-CRP > 3 mg/L.

The primary exposure was platelet count (LBXPLTSI, ×10³/µL). We examined platelets in two ways: (i) categorically as “high-normal” (≥ 300×10³/µL) versus < 300×10³/µL, and (ii) continuously using restricted cubic splines with prespecified internal knots at 150, 250, 350, and 450×10³/µL to flexibly model potential non-linearity across the clinically relevant range. The primary outcome was metabolic syndrome (MetS) defined per NCEP ATP-III criteria as the presence of ≥ 3 of 5 components: central adiposity (waist circumference; sex-specific thresholds), hypertriglyceridemia (triglycerides ≥ 150 mg/dL or lipid-lowering therapy), low HDL-cholesterol (sex-specific thresholds or therapy), elevated blood pressure (systolic ≥ 130 mmHg and/or diastolic ≥ 85 mmHg or antihypertensive therapy), and impaired fasting glucose (≥ 100 mg/dL or glucose-lowering therapy). When multiple blood pressure readings were present, we used the mean of up to three measurements.

Confounders were prespecified a priori based on clinical and epidemiologic plausibility: age (years), sex (male/female), race–ethnicity (six NHANES categories), poverty–income ratio (continuous), body mass index (BMI, kg/m²), hs-CRP (mg/L, continuous), smoking (ever/100 cigarettes; current smoking frequency), and physical activity (vigorous activity yes/no; activity frequency). These variables were chosen to adjust for sociodemographic, adiposity-related, and inflammatory determinants that may influence both platelet counts and the risk of MetS.

Item non-response exceeded 5% for several covariates and formal Hawkins and Anderson–Darling tests rejected missing completely at random, indicating a plausible missing-at-random (MAR) mechanism. Multiple imputation by chained equations (MICE) was therefore implemented using the mice package in R, generating 20 imputed data sets with predictive mean matching (PMM) for continuous variables to preserve distribution shape and avoid implausible values, and logistic or polytomous regression for binary and unordered categorical variables respectively. Ten Gibbs iterations were sufficient for convergence, verified by stable trace plots of variable means/standard deviations and potential-scale-reduction factors < 1.05 across chains. The predictor matrix, derived via quickpred() with mincor = 0.05 and minpuc = 0.25, excluded structural design variables (SEQN, strata, PSUs, weights) to prevent perfect prediction and forced in adiposity, lipid, blood-pressure, and glycemic components as auxiliary predictors to strengthen the MAR assumption. Derived outcomes were specified as passive equations so that each iteration recalculated them deterministically from imputed component variables, maintaining internal logical consistency. Imputed data sets were analyzed with survey-weighted logistic models inside the with() function; coefficients and standard errors were pooled using Rubin’s rules, thereby combining within- and between-imputation variance to yield valid inference. Monte-Carlo error diagnostics confirmed that the Monte-Carlo error for each pooled estimate was < 10% of its corresponding standard error, ensuring numerical stability.

We summarized participant characteristics by platelet category using survey-weighted means (continuous) and proportions (categorical). Differences between groups were evaluated using survey-adjusted t-tests and Rao–Scott χ² tests with second-order correction. The primary association between platelets and MetS was estimated with survey-weighted logistic regression: a fully adjusted model included platelet category (≥ 300 vs < 300×10³/µL) and all prespecified confounders. To evaluate potential dose–response and non-linearity, we replaced platelet category with the spline term for platelet count (knots at 150/250/350/450×10³/µL) and contrasted this model to a nested model with a linear platelet term using a Rao–Scott Wald likelihood-ratio test. Because inflammation may lie on the pathway between adiposity and thrombopoiesis, we conducted an exploratory effect-modification analysis stratifying by hs-CRP (≤ 3 vs > 3 mg/L). For interpretability, we generated model-based predicted probabilities of MetS with 95% confidence intervals across the platelet range, holding continuous covariates at their survey-weighted means and categorical covariates at reference distributions. All analyses were conducted in using R (version 4.4.2). A P-value of < 0.05 was deemed statistically significant.

The present analysis of U.S. adults in NHANES cycles I and P found no evidence that routine platelet count—treated either as a high-normal categorical contrast or as a continuous exposure—adds independent information for prevalent metabolic syndrome (MetS) when models appropriately adjust for sociodemographic factors, central adiposity, lipids, blood pressure, glycemia, smoking and physical activity patterns, and systemic low-grade inflammation indexed by high-sensitivity C-reactive protein (hs-CRP). Our survey-weighted logistic models were stable across specifications, and formal tests of nonlinearity did not support departures from linearity in dose–response, yielding a largely flat risk surface between approximately 150–400×10^3/µL, with imprecise, non-significant widening of uncertainty at the extreme upper tail where data are sparse. These results, taken together, indicate that while platelets track with adverse phenotypes in crude comparisons, they do not appear to function as an independent screening biomarker of MetS in the general adult population once established confounding domains are rigorously controlled using complex-survey inference.

Stratified exploration by inflammatory milieu suggested a biologically coherent but statistically non-decisive pattern: among participants with hs-CRP > 3 mg/L, predicted MetS probability rose more steeply with higher platelets than among those with hs-CRP ≤ 3 mg/L, yet the platelet × inflammation interaction failed conventional significance thresholds in fully adjusted models using design-based variance estimators. This combination—directionally consistent divergence with wide, overlapping confidence bands—hints that any effect modification by systemic inflammation is likely weak, context-dependent, or overwhelmed by the dominant roles of adiposity and glycemic dysregulation in the integrated MetS construct. Given the single time-point nature of CBC and hs-CRP in NHANES, regression dilution and short-term biologic variability probably attenuate true associations, pushing findings toward the null and encouraging cautious interpretation.

These null associations, while perhaps counterintuitive in light of the well-known nexus of inflammation, adiposity, and thrombopoiesis, are congruent with key features of MetS epidemiology and pathobiology. MetS is a syndromic clustering—abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, and dysglycemia—that substantially increases downstream risk of type 2 diabetes and atherosclerotic cardiovascular disease, and its prevalence has remained high in U.S. adults over the last decade despite some stabilization, underscoring the public-health premium on early, scalable risk stratification [1, 3]. Contemporary prevention guidance and screening paradigms emphasize anthropometry, standard chemistries, and blood pressure; routine hematologic indices from the complete blood count (CBC) are seldom featured in guideline-driven algorithms for MetS or prediabetes/diabetes screening, which is consistent with our finding that platelet count did not improve discrimination beyond core risk domains [24, 25].

Biologically, adipose inflammation and cytokine signaling can up-regulate hepatic thrombopoietin (TPO) and augment megakaryopoiesis, with interleukin-6 (IL-6) playing a central role in reactive thrombocytosis and platelet “priming” [9, 26, 27] Activated platelets interact bidirectionally with dysfunctional endothelium and innate immunity, elaborating mediators that may amplify insulin resistance and vascular injury, while insulin itself exerts direct anti-aggregatory effects that are blunted in insulin-resistant states [28, 29]. Observational studies have reported associations between platelet indices (e.g., mean platelet volume, platelet-to-lymphocyte ratio) and adverse cardiometabolic phenotypes, but effect sizes frequently shrink or dissipate after rigorous adjustment for adiposity and inflammatory covariates, and many prior reports derive from convenience samples without survey design correction [30, 31]. Against this mechanistic backdrop, our nationally representative, design-based estimates suggest that whatever signal platelet count carries for prevalent MetS is largely collinear with the dominant axes of adiposity and inflammation captured by BMI/waist and hs-CRP.

Compared with earlier clinic-based or single-center studies suggesting stronger platelet–MetS relationships, our work leverages NHANES’ multistage probability design with proper weights, strata, and clusters to obtain population-level inference and valid standard errors; this methodological step alone can materially attenuate spurious associations seen in unweighted analyses [32]. Moreover, our dose–response modeling used restricted cubic splines to probe for thresholding or saturation not apparent under linearity, and formal Wald tests within survey-GLMs provided an appropriately conservative evaluation of nonlinearity [33]. We also addressed non-MCAR missingness with multiple imputation by chained equations and Rubin’s combining rules, a principled strategy that reduces bias from complete-case restriction and is well-validated for epidemiologic data structures similar to NHANES [34].

Important limitations temper over-interpretation. First, the cross-sectional design precludes temporal ordering and leaves confounding and mediation intertwined: for example, hs-CRP may mark shared upstream inflammatory drive (confounding) and simultaneously lie on the path from adiposity to thrombopoiesis (mediation), complicating “independent effect” claims. Second, single time-point CBC/hs-CRP measures are susceptible to week-to-week variability from intercurrent subclinical infections, acute stressors, or diurnal factors; such classical measurement error generally biases toward the null in logistic models. Third, while we examined the entire “normal” platelet range, the precision at the extreme tails is limited by design; wider confidence intervals at > 450×10^3/µL were expected, and influential observations can shape spline tails without implying biological thresholds. Fourth, residual confounding from diet, infection burden, autoimmune conditions, or medications beyond our standard surrogates remains possible; however, given the breadth of our adjustment set and the magnitude of observed nulls, substantial hidden confounding would be required to mask a clinically meaningful association. Finally, generalizability is anchored to non-institutionalized U.S. adults in 2017–2020 and 2011–2012; extrapolation to pediatric, geriatric, or disease-enriched settings should be cautious.

Clinically, these findings argue against adopting platelet count as an additional stand-alone screen for MetS in general populations, reinforcing the primacy of established, low-cost measures—waist circumference, blood pressure, fasting lipids and glucose—and lifestyle risk factors already embedded in primary-care screening [1]. From a pathophysiologic standpoint, the descriptive co-variation of higher platelets with worse adiposity and inflammation likely reflects shared upstream drivers (adipose cytokine signaling, IL-6/TPO axis), rather than an independent, causal role of platelets in the genesis of the metabolic syndrome phenotype [9]. The exploratory divergence of spline curves by hs-CRP is biologically plausible, yet the absence of a statistically significant interaction term suggests that any effect modification by inflammatory status is modest relative to the overwhelming contribution of adiposity and its metabolic sequelae [3].

Future work should prioritize longitudinal designs with repeated measures of CBC indices and inflammatory biomarkers to address temporality and cumulative exposure—features that NHANES cannot provide within a single cross-sectional cycle. It will also be informative to test alternative platelet phenotypes (mean platelet volume, immature platelet fraction, platelet reactivity markers) and composite inflammatory ratios (e.g., platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio) under the same rigorous survey-weighted and multiply imputed framework, as some of these indices may better capture thrombo-inflammatory activation than total count alone. PMC Methodologically, the application of causal inference tools (e.g., Mendelian randomization using variants in thrombopoietin/c-Mpl signaling or IL-6 pathways) could help adjudicate whether genetically elevated platelet counts influence metabolic traits apart from shared confounding; integrating deep inflammatory phenotyping and multi-omics would further delineate network-level links between adiposity, thrombopoiesis, and insulin resistance [27].

In sum, using nationally representative data and modern design-based, multiply imputed modeling with flexible dose–response, we found that routine platelet count does not independently associate with prevalent MetS, and we detected no compelling evidence of nonlinearity across the “normal” platelet range. While exploratory patterns by hs-CRP invite hypothesis-driven longitudinal replication, current evidence does not justify including platelet count as an early screening biomarker for MetS in general clinical practice, where resources and attention remain better directed toward anthropometry, blood pressure, standard lipids, fasting glucose, and lifestyle modification.